Table 6 MUQUBIA agreement with neuropathologic assessments.

ID	Neuropathology			MUQUBIA				LRAP
ID	ABC score	Lewy body pathology	FTLD with tau or other tauopathy	AD probability	DLB probability	FTD probability	CN probability
011_S_0183	High ADNC	Neocortical (diffuse)	No	0.18	0.82	0.00	0.00	95%
027_S_4938	High ADNC	Amygdala (predominant)	Yes	0.37	0.05	0.58	0.01
027_S_4962	High ADNC	Neocortical (diffuse)	Yes	0.46	0.15	0.08	0.32
033_S_0724	High ADNC	Neocortical (diffuse)	No	0.03	0.97	0.00	0.00
127_S_5058	Intermediate ADNC	Neocortical (diffuse)	No	0.47	0.26	0.26	0.01
PDDJ916LE2	Intermediate ADNC	Limbic (transitional)	No	0.61	0.29	0.09	0.02
PDEZ829YJX	High ADNC	Neocortical (diffuse)	No	0.20	0.77	0.01	0.03
NACC047218	High ADNC	No	No	0.54	0.06	0.29	0.11
NACC131130	High ADNC	Amygdala (predominant)	No	0.42	0.56	0.02	0.00

The table reports the LRAP score derived considering the multilabel neuropathological ground truth (Montine’s criteria) of 9 subjects of our test set and the MUQUBIA classification probabilities. All the 9 subjects had cognitive impairment. 'Intermediate' or 'High' level of ADNC should be considered adequate explanation of AD dementia. 'Limbic', 'Neocortical' or 'Amygdala-predominant' level should be considered adequate explanation of Lewy Body Diseases and this does not preclude contribution of other diseases (e.g.: 'Amygdala-predominant LBD' typically occurs in the context of advanced AD neuropathologic change). Presence of frontotemporal lobar degeneration with tau or other tauopathy and subtypes were labeled as ‘Yes’.
LRAP label ranking average precision, ADNC NIA-AA Alzheimer’s disease neuropathologic change, ABC Aβ/amyloid plaques (A)—NFT stage (B)—and neuritic plaque score (C), FTLD frontotemporal lobar degeneration, AD Alzheimer’s dementia, DLB dementia with Lewy body, FTD frontotemporal dementia, CN cognitive normal.

Quick links

Search